Clinical implications of first-trimester screening

Clinics in Laboratory Medicine

Volumn 30, Issue 3, 2010, Pages 605-611

  Chasen, Stephen T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aneuploidy risk assessment; First trimester screening; Pregnancy; Prenatal screening

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CHROMOSOME ABERRATION; DOWN SYNDROME; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INVASIVE PROCEDURE; MEDICAL ABORTION; MEDICAL EDUCATION; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; REVIEW; SENSITIVITY AND SPECIFICITY; ANEUPLOIDY; FEMALE; PREDICTIVE VALUE; PREGNANCY; RISK ASSESSMENT;

ANEUPLOIDY; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 77954778670     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.04.014     Document Type: Review

References (34)

1. Avgidou K., Papageorghiou A., Bindra R., et al. Prospective first-trimester screening for Trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005, 192:1761-1767.
2. Malone F.D., Canick J.A., Ball R.H., et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005, 353:2001-2011.
3. ACOG Committee on Practice Bulletins-Obstetrics Screening for fetal chromosomal abnormalities 2001, ACOG Practice Bulletin #27, The American College of Obstetricians and Gynecologists, Washington, DC.
4. ACOG Committee on Practice Bulletins-Obstetrics Screening for fetal chromosomal abnormalities 2007, ACOG Practice Bulletin #27, The American College of Obstetricians and Gynecologists, Washington, DC.
5. Driscoll D.A., Morgan M.A., Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol 2009, 200:459. e1-9.
6. Boyd P.A., Devigan C., Khoshnood B., et al. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG 2008, 115:689-696.
7. Nadler H.L., Gerbie A.B. Role of amniocentesis in the intrauterine detection of genetic disorders. N Engl J Med 1970, 282:596-599.
8. Simoni G., Brambati B., Danesino C., et al. Efficient direct chromosome analyses and enzyme determinations from chorionic villi samples in the first trimester of pregnancy. Hum Genet 1983, 63:349-357.
9. Merkatz I.R., Nitowsky H.M., Macri J.N., et al. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984, 148:886-894.
10. Phillips O.P., Elias S., Shulman L.P., et al. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992, 80:353-358.
11. Haddow J.E., Palomaki G.E., Knight G.J., et al. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994, 330:1114-1118.
12. Benacerraf B.R., Frigoletto F.D., Laboda L.A. Sonographic diagnosis of Down syndrome in the second trimester. Am J Obstet Gynecol 1985, 153:49-52.
13. Cheffins T., Chan A., Haan E.A., et al. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG 2000, 107:1453-1459.
14. Benn P.A., Fang M., Egan J.F. Trends in the use of second trimester maternal serum screening from 1991 to 2003. Genet Med 2005, 7(5):328-331.
15. Perni S.C., Predanic M., Kalish R.B., et al. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 2006, 195:236-239.
16. Chasen S.T., Sharma G., Kalish R.B., et al. First-trimester screening for aneuploidy with fetal nuchal translucency in a United States population. Ultrasound Obstet Gynecol 2003, 22:149-151.
17. Chasen S.T., McCullough L.B., Chervenak F.A. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population?. Am J Obstet Gynecol 2004, 190:769-774.
18. Fang Y.M., Benn P., Campbell W., et al. Down syndrome screening in the United States in 2001 and 2007: a survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2009, 201:97. e1-5.
19. Muller P.R., Cocciolone R., Haan E.A., et al. Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005. Am J Obstet Gynecol 2007, 196:315. e1-7.
20. Mansfield C., Hopfer S., Marteau T.M. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. Prenat Diagn 1999, 19:808-812.
21. Morris J.K., Alberman E. Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. BMJ 2009, 339:b3794.
22. Jou H.J., Kuo Y.S., Hsu J.J., et al. The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening. Prenat Diagn 2005, 25:665-670.
23. Pazol K., Gamble S.B., Parker W.Y., et al. Centers for Disease Control and Prevention (CDC). Abortion surveillance-United States, 2006. MMWR Surveill Summ 2009, 58:1-35.
24. Jones R.K., Zolna M.R., Henshaw S.K., et al. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health 2008, 40:6-16.
25. Chasen S.T., Kalish R.B., Chervenak F.A. Gestational age at abortion: the impact of first-trimester risk assessment for aneuploidy. Am J Obstet Gynecol 2006, 195:839-842.
26. Kalish R.B., Thaler H.T., Chasen S.T., et al. First- and second-trimester ultrasound assessment of gestational age. Am J Obstet Gynecol 2004, 191:975-978.
27. Ewigman B.G., Crane J.P., Frigoletto F.D., et al. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group. N Engl J Med 1993, 329:821-827.
28. Lee Y.M., Cleary-Goldman J., Thaker H.M., et al. Antenatal sonographic prediction of twin chorionicity. Am J Obstet Gynecol 2006, 195:863-867.
29. Timor-Tritsch I.E., Fuchs K.M., Monteagudo A., et al. Performing a fetal anatomy scan at the time of first-trimester screening. Obstet Gynecol 2009, 113:402-407.
30. Clur S.A., Ottenkamp J., Bilardo C.M. The nuchal translucency and the fetal heart: a literature review. Prenat Diagn 2009, 29:739-748.
31. Chasen S.T., Kalish R.B. Abortion for structural anomalies: the impact of early ultrasound. Am J Obstet Gynecol 2009, 201:S156.
32. Dugoff L., Hobbins J.C., Malone F.D., et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004, 191:1446-1451.
33. Goetzl L., Krantz D., Simpson J.L., et al. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004, 104:30-36.
34. Chasen S.T., Martinucci S., Perni S.C., et al. First-trimester biochemistry and outcomes in twin pregnancy. J Reprod Med 2009, 54(5):312-314.